These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31801393)

  • 1. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
    Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
    J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
    Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
    Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
    Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
    Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
    Yuan Z; DeFalco F; Wang L; Hester L; Weaver J; Swerdel JN; Freedman A; Ryan P; Schuemie M; Qiu R; Yee J; Meininger G; Berlin JA; Rosenthal N
    Curr Med Res Opin; 2020 Jul; 36(7):1117-1124. PubMed ID: 32338068
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study.
    Amos TB; Montejano L; Juneau P; Bolge SC
    J Med Econ; 2017 Mar; 20(3):303-313. PubMed ID: 27826987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Clin Drug Investig; 2020 Jul; 40(7):665-669. PubMed ID: 32449083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
    Real J; Vlacho B; Ortega E; Vallés JA; Mata-Cases M; Castelblanco E; Wittbrodt ET; Fenici P; Kosiborod M; Mauricio D; Franch-Nadal J
    Cardiovasc Diabetol; 2021 Jul; 20(1):139. PubMed ID: 34243779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.
    Wang Y; Desai M; Ryan PB; DeFalco FJ; Schuemie MJ; Stang PE; Berlin JA; Yuan Z
    Diabetes Res Clin Pract; 2017 Jun; 128():83-90. PubMed ID: 28448895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
    Kashiwagi A; Shoji S; Onozawa S; Kosakai Y; Waratani M; Ito Y
    J Diabetes Investig; 2022 Jul; 13(7):1175-1189. PubMed ID: 35243799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
    Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
    BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
    Kashiwagi A; Shoji S; Kosakai Y; Yoshinaga Y; Rokuda M
    J Diabetes Investig; 2024 Mar; 15(3):374-387. PubMed ID: 38112598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
    Buysman EK; Anderson A; Bacchus S; Ingham M
    Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.